« Return to News | Awards & Advancement

Syndax appoints Pappas to board of directors

Friday, April 6, 2012 03:26 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has added Arthur M. Pappas to the ranks of its board of directors.

Pappas is the founder and managing partner of Pappas Ventures, a Research Triangle Park, N.C.-based venture capital firm that invests nationally in the life science industry. Pappas and his team of investment, biotechnology and medical experts manage over $350 million and oversee investments in more than 40 portfolio companies. 

Prior to founding Pappas Ventures in 1994, he held senior level leadership positions at several multinational pharmaceutical companies, including Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and Dow Chemical Company. In addition to Syndax, Mr. Pappas is currently a director of Afferent Pharmaceuticals, CardioDx, CeNeRx, Chimerex, CoLucid and TyRx. He was also involved in Plexxikon, which was sold to Daiichi Sankyo last year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.